QIAGEN (NYSE:QGEN) Stock Rating Lowered by Wall Street Zen

Key Points

• QIAGEN has been downgraded from a "buy" rating to a "hold" rating by Wall Street Zen, reflecting a shift in analyst sentiment towards the stock.
• Despite the downgrade, several brokerages maintain a "hold" or "buy" rating, with a current consensus target price of $49.40 and a recent price target increase from Bank of America to $53.00.
• QIAGEN reported strong earnings, matching analyst estimates with an EPS of $0.60 and a year-over-year revenue increase of 7.7%, indicating solid financial health.

QIAGEN (NYSE:QGEN - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Friday.

Several other brokerages have also recently issued reports on QGEN. Cowen restated a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Bank of America increased their price target on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Weiss Ratings reiterated a "hold (c+)" rating on shares of QIAGEN in a research report on Saturday, September 27th. UBS Group increased their price target on shares of QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Finally, Barclays set a $53.00 price target on shares of QIAGEN and gave the stock an "overweight" rating in a research report on Thursday. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $49.40.

QIAGEN Stock Performance

QGEN stock traded up $0.59 on Friday, hitting $46.83. The company had a trading volume of 1,069,740 shares, compared to its average volume of 1,132,142. QIAGEN has a 12-month low of $37.63 and a 12-month high of $51.88. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The stock's 50-day simple moving average is $47.43 and its 200 day simple moving average is $45.24. The stock has a market cap of $10.41 billion, a price-to-earnings ratio of 27.67, a P/E/G ratio of 2.44 and a beta of 0.66.

QIAGEN (NYSE:QGEN - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The company had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. During the same quarter last year, the company posted $0.55 earnings per share. The firm's quarterly revenue was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, equities research analysts expect that QIAGEN will post 2.26 earnings per share for the current fiscal year.

Institutional Trading of QIAGEN

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in QIAGEN by 375.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company's stock valued at $55,000 after acquiring an additional 980 shares during the last quarter. Osaic Holdings Inc. increased its holdings in QIAGEN by 101.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company's stock valued at $185,000 after acquiring an additional 1,951 shares during the last quarter. Orion Porfolio Solutions LLC increased its holdings in QIAGEN by 120.6% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 29,361 shares of the company's stock valued at $1,411,000 after acquiring an additional 16,054 shares during the last quarter. Squarepoint Ops LLC increased its holdings in QIAGEN by 11.4% in the 2nd quarter. Squarepoint Ops LLC now owns 13,548 shares of the company's stock valued at $651,000 after acquiring an additional 1,386 shares during the last quarter. Finally, Neuberger Berman Group LLC grew its stake in shares of QIAGEN by 57.5% in the 2nd quarter. Neuberger Berman Group LLC now owns 30,478 shares of the company's stock worth $1,463,000 after buying an additional 11,126 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.